




Antibody-Drug Conjugates

What are Antibody-Drug Conjugates ?

Antibody-Drug Conjugates (ADCs) are the outcome of merging monoclonal antibodies with cytotoxic drugs using a linker. The monoclonal antibody selectively targets antigens overexpressed on cancer cells, ensuring precise payload delivery while sparing healthy tissues.




Clinical stage of current ADC under development


A fast-emerging class of therapeutic agents...



... however, they represent about 16% of all the therapeutic antibodies currently under clinical development.



ADCs currently on the European market



Source: Globaldata / Data from May 2023